# Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy

> **NCT06437431** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Fondation Ophtalmologique Adolphe de Rothschild** · enrollment: 304 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** glenzocimab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06437431
- **Lead sponsor:** Fondation Ophtalmologique Adolphe de Rothschild
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2030-10
- **Final completion:** 2030-10
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06437431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06437431, "Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06437431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*